Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 116 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pneumococcal Vaccination Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines

NCT03104075
View directory record Official record
Conditions
Pneumonia, Aging
Interventions
Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein, Pneumococcal Vaccine Polyvalent
Biological
Lead sponsor
The Jackson Laboratory
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 24, 2026, 5:13 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children

NCT06038617
View directory record Official record
Conditions
Fever After Vaccination, Fever, Seizures Fever
Interventions
mRNA COVID-19 Vaccine, Routine Childhood Vaccinations
Biological
Lead sponsor
Duke University
Other
Eligibility
6 Months to 4 Years
Enrollment
347 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
5
States / cities
Oakland, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 24, 2026, 5:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers

NCT00279734
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tetanus + pnemococcal vaccines alone, Abatacept + Vaccines
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
3
States / cities
Lenexa, Kansas • Baltimore, Maryland • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Oct 24, 2026, 5:13 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

NCT07425392
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31-valent pneumococcal conjugate vaccine, PCV20
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
50 Years and older
Enrollment
752 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
30
States / cities
Chinle, Arizona • Phoenix, Arizona • Whiteriver, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 24, 2026, 5:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)

NCT03620162
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Prevnar 13™, V114, RotaTeq™, Pentacel™, RECOMBIVAX HB™, HIBERIX™, M-M-R™ II, VARIVAX™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
42 Days to 90 Days
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
22
States / cities
Birmingham, Alabama • Dothan, Alabama • Jonesboro, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 24, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Results available

Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

NCT01349569
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Allogeneic Myeloma Vaccine, Prevnar-13
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 24, 2026, 5:13 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults

NCT03039491
View directory record Official record
Conditions
HIV Lipodystrophy, Aging
Interventions
Pneumococcal polysaccharide vaccine 23 valent, 13 valent conjugated pneumococcal vaccine
Biological
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 24, 2026, 5:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of the Immune Response After Vaccination in Multiple Myeloma Patients

NCT02294487
View directory record Official record
Conditions
Multiple Myeloma, Myeloma, Multiple, Myeloma-Multiple
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 24, 2026, 5:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting

NCT00622843
View directory record Official record
Conditions
HIV Infections, Streptococcus Pneumoniae
Interventions
pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine
Biological
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2013
U.S. locations
6
States / cities
San Diego, California • Washington D.C., District of Columbia • Tripler AMC, Hawaii + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 24, 2026, 5:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

NCT00806195
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine, IPV (Inactivated Polio Vaccine) Vaccine, Pneumococcal conjugate Vaccine, MMR (Measles, Mumps, and Rubella) Vaccine, Varicella Vaccine, Hepatitis A Virus
Biological
Lead sponsor
Novartis
Industry
Eligibility
55 Days to 89 Days
Enrollment
7,744 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
130
States / cities
Birmingham, Alabama • Dothan, Alabama • Tuscon, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Oct 24, 2026, 5:13 PM EDT
Completed Not applicable Interventional Results available

Perturbing of HIV Reservoir With Immune Stimulation

NCT02707692
View directory record Official record
Conditions
AIDS, HIV
Interventions
Fluarix, Pneumovax, Placebo
Biological · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 24, 2026, 5:13 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Pneumococcal Post-Vaccination Titers

NCT02726347
View directory record Official record
Conditions
Smokers, Elderly, Asthma, COPD, Recurrent Infections
Interventions
PPV-23
Biological
Lead sponsor
National Jewish Health
Other
Eligibility
19 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 24, 2026, 5:13 PM EDT
Completed Not applicable Interventional

Respiratory Disease Management

NCT01543217
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
RT management, Ususal care
Other
Lead sponsor
Barnes-Jewish Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 24, 2026, 5:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants

NCT01000974
View directory record Official record
Conditions
Haemophilus Influenzae Type b
Interventions
GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108), ActHIB™, Pentacel™, Pediarix™, Prevnar 13™, Rotarix™, Engerix™-B, Infanrix™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
4,003 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
63
States / cities
Dothan, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 24, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Results available

Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma

NCT01245673
View directory record Official record
Conditions
Myeloma
Interventions
Prevnar- Pneumococcal Conjugate Vaccine (PCV), Activated/costimulated autologous T-cell, Revlamid® (Lenalidomide), MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)
Biological · Other · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 24, 2026, 5:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

NCT02034773
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-220, Placebo
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 24, 2026, 5:13 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

NCT03636906
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV (GSK3389245A) lower dose formulation vaccine, RSV (GSK3389245A) higher dose formulation vaccine, GSK's multicomponent meningococcal B vaccine, Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine, GSK's pneumococcal polysaccharide conjugate vaccine, GSK's meningococcal group A, C, W-135 and Y conjugate vaccine, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 7 Months
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • Nampa, Idaho • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 24, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Results available

Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients

NCT00323557
View directory record Official record
Conditions
Leukemia
Interventions
Sargramostim (GM-CSF), Pneumococcal Vaccine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 24, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older

NCT00741039
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Prostate Cancer
Interventions
inactivated influenza vaccine and the 23- valent pneumococcal vaccine, inactivated influenza vaccine and the PPV23 vaccine (Pneumovax)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 24, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

NCT00129129
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine, ActHIB, Pediarix, Prevnar, Menomune
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 15 Months
Enrollment
756 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
27
States / cities
Little Rock, Arkansas • Fountain Valley, California • Centennial, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 24, 2026, 5:13 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

NCT06693895
View directory record Official record
Conditions
Chickenpox
Interventions
Investigational varicella vaccine, Marketed varicella vaccine, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Huntington Park, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 24, 2026, 5:13 PM EDT
Completed Phase 3 Interventional Results available

Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS

NCT00963235
View directory record Official record
Conditions
HIV Infections, Pneumococcal Infections
Interventions
13-valent pneumococcal conjugate vaccine, Blood draw
Biological · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Oct 24, 2026, 5:13 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)

NCT01597492
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab plus Early Vaccination, Belimumab plus Late Vaccination
Biological
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
15
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Shreveport, Louisiana + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 24, 2026, 5:13 PM EDT
Completed Phase 4 Interventional Results available

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

NCT04080531
View directory record Official record
Conditions
Plasma Cell Neoplasm
Interventions
Pneumococcal 13-valent Conjugate Vaccine, Trivalent Influenza Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 24, 2026, 5:13 PM EDT